VRTX
Vertex Pharmaceuticals Incorporated$496.73-0.58% 1D· price as of Jun 30, 8:32 PM+12.03% over 1Y
Compare:VRTX
Mkt Cap
$126.1B
P/E
29.5×
Fwd P/E
23.1×
PEG
1.82
P/B
6.5×
P/S
10.3×
EV/EBITDA
24.3×
Beta
0.31
Div Yield
0.0%
Payout
0.0%
ROE
24.2%
Net Margin
35.5%
Short % Flt
1.8%
Inst. Own
98.0%
52-wk low $362.50$496.7352-wk high $507.92
+37.0% above low-2.2% from high
Seasonality — avg monthly return
Strongest Jan 7.4% · weakest Aug -3.1%Jan
+7.4
Feb
-2.7
Mar
+2.2
Apr
+1.5
May
-0.6
Jun
+4.3
Jul
+1.6
Aug
-3.1
Sep
-2.6
Oct
+5.0
Nov
+0.1
Dec
+2.8
Average month-over-month return per calendar month over the available history (~5 yrs); hover for the share of positive months. Past seasonality isn't predictive.
Ask AI about Vertex Pharmaceuticals Incorporated
Gemini · web searchSearches the live web for current news & events plus this company's financials — and you can keep asking follow-up questions.
VRTX — recent news
Loading headlines…
Quality scorecard
vs Biotechnology · 8 peers · percentile rank
69 / 100
Strong
ROIC20.8%
86
ROE21.2%
57
Gross margin86.2%
86
Operating margin37.9%
86
FCF yield2.6%
14
Net debt / EBITDAnet cash
86
Percentile vs 8 Biotechnology peers — higher = better (leverage inverted: less debt ranks higher). The faint tick is the peer median; the score is the average percentile. Annual fundamentals.